Mass spectrometry should be utilized effectively to optimize biosimilar analysis, which can reduce development time and cost.
Indu Javeri
Advertisement
INDU JAVERI is president and CEO, CuriRx, Inc., Wilmington, MA.
Articles by Indu Javeri
Advertisement
Latest Updated Articles
Accelerating Biosimilar AnalysisPublished: October 2nd 2019 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
PharmTech Weekly News Roundup – Week of November 3, 2025
2
AAPS PharmSci 360: Enhancing Bioanalysis with AI and Other Technologies
3
New Dosage Forms and Delivery Systems Driving 505(b)(2) Success
4
Why Investment Strategies Matter for Advancing Pharmaceutical Technologies
5
